At this year’s Community Oncology Conference, new early-phase data from the Community Oncology Alliance’s Quality of Care Study have added to a growing body of evidence challe ...
Sabari, MD, discusses exploring combination approaches as the next research step with zongertinib in patients with HER2 ...
Sabari, MD, discusses dosing, administration, and optimal patient management when using zongertinib to treat patients with ...
Although PTCy has enabled a surge in mismatched unrelated donor (MMUD) transplantations, its standard administration comes ...
Sabari, MD, discusses his personal experience treating patients with zongertinib as part of the Beamion LUNG‑1 trial, which ...
NIH funding disruptions threaten cancer trial pipelines, stalling early detection and new therapies—what oncologists and ...
An evidence gap persists in BCG-unresponsive NMIBC because pivotal approvals rely on single-arm studies, making indirect ...
The TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) demonstrated a statistically significant ...
Financial toxicity is pervasive in rural oncology, with 53% reporting unaffordable care, 50% carrying medical debt, and 70% ...
Enzalutamide Plus Leuprolide Extends Treatment Suspension in Biochemically Recurrent Prostate Cancer
An ITT reanalysis assigning 0-month suspension to non-suspenders addressed imbalance in suspension rates (90% combination, 86 ...
Lilit Karapetyan, MD, MS, discusses the importance of considering TIL therapy for melanoma in advance and not as a last ...
Two pre-TURBT 40-mg intravesical mitomycin-C instillations significantly improved long-term recurrence outcomes versus TURBT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results